BIIB
USDBiogen Inc. Common Stock
リアルタイム価格
価格チャート
主要指標
市場指標
始値
$129.550
高値
$129.580
安値
$124.680
出来高
1.14M
企業ファンダメンタルズ
時価総額
18.3B
業種
Drug Manufacturers - General
国
United States
取引統計
平均出来高
1.48M
取引所
NMS
通貨
USD
52週レンジ
関連ニュース
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN)There are currently no therapies specifically approved
New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA
New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SPINRAZA®
RBC Capital Reiterates Outperform on Biogen, Maintains $213 Price Target
RBC Capital analyst Brian Abrahams reiterates Biogen with a Outperform and maintains $213 price target.
HC Wainwright & Co. Reiterates Buy on Biogen, Maintains $187 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Biogen with a Buy and maintains $187 price target.
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA
Piper Sandler Reiterates Neutral on Biogen, Maintains $115 Price Target
Piper Sandler analyst David Amsellem reiterates Biogen with a Neutral and maintains $115 price target.
Wedbush Reiterates Neutral on Biogen, Maintains $121 Price Target
Wedbush analyst Laura Chico reiterates Biogen with a Neutral and maintains $121 price target.
関連株式
最新情報を入手
価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。